You are here: Industry Insights > Immuno-Oncology

News List

Make that four drug approvals for Pfizer’s oncology unit in less than two months. In a welcome streak for the pharma giant—what with Lyrica generics looming—the FDA handed out fiercepharma
December 10, 2018
Roche’s immuno-oncology rivals are hurtling toward a showdown in previously untreated kidney cancer. But the Swiss drugmaker has decided to pull its horse out of the race.
BMS flips negative NICE ruling on Opdivo, winning thumbs-up for preventing melanoma relapse fiercepharma
December 04, 2018
In September, Britain’s drug-cost watchdog, The National Institute for Health and Care Excellence (NICE), said Bristol-Myers Squibb did not make a convincing enough case that PD-1
TRACON Pharmaceuticals and I-Mab Biopharma Announce Strategic Partnerships for Multiple Immuno-Oncology Programs pharmafocusasia
December 03, 2018
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer......
A Powerful Catalyst On The Horizon Dr. Tran
November 26, 2018
“Looking out for mispriced betting opportunities and betting heavily when the odds are overwhelmingly in your favor is the ticket to wealth.” - Mohnish Pabrai
Nobel Prize awarded to immuno-oncology innovators pharmafile
November 20, 2018
The Nobel Prize for physiology or medicine has been awarded to both Professor James P Allison and Tasuku Honjo for the discoveries they have made in the area of immuno-oncology.
First U.S.-Cuba biotech JV to bring Cuban-developed cancer vaccines to the U.S. fiercepharma
November 09, 2018
Three years after the U.S. and Cuba restored their diplomatic relations, the first biotech joint venture between institutions from the two countries has launched with the
Invectys raises €15M series A to fund DNA cancer vaccine study in CLL fiercepharma
November 09, 2018
French startup Invectys hopes its cancer vaccine can win a spot in immuno-oncology combination therapies, and it just nabbed €15 million ($17 million) in series A funding to...
Gilead pays $50M to team up with synthetic lethality startup Tango fiercebiotech
November 02, 2018
Gilead is paying $50 million upfront to enter into an immuno-oncology collaboration with Tango Therapeutics. The agreement gives Gilead the option to pick up the worldwide rights to five targets...
Calithera compound empowers immuno-oncology therapies by targeting metabolic signals fiercebiotech
November 02, 2018
Can targeting one metabolic signaling pathway have completely opposite effects on different subsets of T cells? In the case of glutamine metabolism, the answer seems to be ...
KSQ grabs $80M to move T-cell treatment for PD-1 resistance into the clinic fiercebiotech
September 29, 2018
KSQ is focusing on cancer at the moment, but plans to expand its CRISPRomics platform to other areas, such as immunology.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page